Teglicar

Drug Profile

Teglicar

Alternative Names: ST-1326

Latest Information Update: 04 Aug 2015

Price : $50

At a glance

  • Originator sigma-tau SpA
  • Class Antihyperglycaemics; Trimethyl ammonium compounds
  • Mechanism of Action Carnitine O-palmitoyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Aug 2015 Discontinued - Phase-II for Type-2 diabetes mellitus in Italy (PO)
  • 11 Sep 2008 Efficacy, adverse events and pharmacokinetics data from a clinical trial in Type 2 diabetes presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD-2008)
  • 05 Mar 2007 Phase-II clinical trials in Type-2 diabetes mellitus in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top